• Adolor Corp., of Exton, Pa., said it will disband its sales force of about 35 people and make other selected reductions to its work force. The company established its sales group in early 2005 in anticipation of a product launch for Entereg (alvimopan) for the management of postoperative ileus later that year. The FDA's approvable letter and a subsequent delay to market entry for Entereg is the reason for the cutback. The sales force has been detailing London-based GlaxoSmithKline plc's anti-thrombotic agent Arixtra under Adolor's co-promotion agreement with GSK, which expires at the end of this year. The company's headcount following the reduction is 128, down from 180. It expects to take a one-time charge of about $2 million to $3 million in the fourth quarter. Adolor also said its senior vice president and chief operating officer, Michael Dougherty, was elected president and CEO and a member of the company's board. He will replace David Madden, who has served as interim president and CEO since August 2005, and who will continue as chairman.

• Centocor Inc., of Horsham, Pa., and Schering-Plough Corp., of Kenilworth, N.J., said the European Commission approved a label extension for Remicade (infliximab) allowing for a shortened infusion time in patients with rheumatoid arthritis. The approval follows a positive opinion by the Committee for Medicinal Products for Human Health of the European Medicines Agency received in September.

• Emergent BioSolutions Inc., of Gaithersburg, Md., completed the fourth quarter deliveries of more than 3 million doses of BioThrax (anthrax vaccine adsorbed) to the Department of Health and Human Services for placement into the nation's strategic national stockpile. The delivery represents fourth-quarter revenue of about $75 million.

• Encysive Pharmaceuticals Inc., of Houston, said the FDA informed the company that its response to the July 24 approvable letter for Thelin (sitaxsentan sodium) 100-mg tablets is not complete. The agency requested that the company provide information in a certain tabular format. Encysive expects to provide the information within several days. (See BioWorld Today, July 26, 2006.)

• Epitome Biosystems, of Waltham, Mass., was awarded a Phase IIb Small Business Innovation Research grant to support development of its protein phosphorylation-profiling product. The product is an antibody array that incorporates Epitome's EpiTag technology to enable qualitative and quantitative measurements of protein phosphorylation. The grant provides $500,000 toward the development of a product for measuring key tyrosine phosphorylation sites that have important roles in many cellular and drug responses.

• OSI Pharmaceuticals Inc., of Melville, N.Y., said its diabetes and obesity subsidiary, Prosidion, granted Bristol-Myers Squibb Co., of New York, a worldwide nonexclusive license under its DPIV patent portfolio for the development and commercialization of DPIV inhibitors to treat Type II diabetes and related indications. OSI will receive an up-front payment, as well as potential future milestone and royalty payments.

• Peregrine Pharmaceuticals Inc., of Tustin, Calif., and Biotecnol SA, of Oeiras, Portugal, agreed to collaborate on the development of targeted immunocytokine agents for cancer and other diseases using Peregrine's Vascular Targeting Agent platform and Biotecnol's Tribody technology to fuse anti-phospholipid targeting agents to one or more cytokines in a Tribody format. Work done in the collaboration is expected to result in a license agreement from Biotecnol to Peregrine for development and commercialization of any resulting agents. Financial terms were not disclosed.

No Comments